Corindus said new motion automations have received FDA clearance for use in coronary and peripheral robotic-assisted procedures.
Amazon’s security drone, life-size Gundam & robotic-assisted surgery
Welcome to Episode 18 of The Robot Report Podcast, which brings conversations with robotics innovators straight to you. Join us every week for discussions with leading roboticists, innovative robotics companies, and other key members of the robotics community. Listeners can subscribe to The Robot Report Podcast on Amazon Music, Apple Podcasts, SoundCloud, Spotify, Google Play, and…
6 types of surgical procedures getting robotic assistance
The range of surgical procedures that robots can assist is widening, even as systems become more specialized.
Remote surgeries, brain procedures demonstrate Corindus CorPath GRX advances
Doctor have now used the CorPath GRX system in a successful brain surgery and to conduct multiple remote surgeries, advancing the state of robot-assisted procedures.
Telesurgery trials mark milestone in India; doctors discuss lessons
A cardiac surgeon in India and one in the U.S. discuss promising developments and remaining challenges around robot-assisted telesurgery.
Corindus Vascular Robotics to be acquired by Siemens Medical Solutions for $1.1B
Corindus Vascular Robotics, whose CorPath GRX has FDA approval for percutaneous coronary and vascular procedures, will be acquired by Siemens Healthineers.
6 robotics applications demonstrating new tech, markets
As robots expand beyond manufacturing, what should developers know about new applications? Here are six examples of robotics needs.
Robotics investments February 2019
Robotics investments totaled at least $4.3 billion in February 2019 in a steep increase from January, which had about $1.4 billion. In addition, companies reported approximately $3.9 billion worth of acquisitions this past month. Any political or economic jitters have not yet harmed the mood for robot deals. The Robotic Industries Association noted yesterday that robot…
Corindus submits CorPath GRX to FDA for robotic neurovascular interventions
Corindus Vascular Robotics this week said it applied to the U.S. Food and Drug Administration for premarket clearance to use its CorPath GRX robotic surgical platform in neurovascular interventions. The Waltham, Mass.-based company has already received FDA clearance for percutaneous coronary interventions (PCI), which it won in 2016, and for peripheral vascular interventions (PVI), which it won last…
Corindus CorPath GRX surgical robot receives clearance in Japan
Corindus Vascular Robotics has won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device. The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions (PCI) procedures, including angioplasty and stent placement. Japan is one of the largest markets in the world for PCIs, according to…
Corindus Raises $25M for CorPath GRX Surgical Robot
Corindus Vascular Robotics inked a private placement deal worth $25 million through the offering of newly-designated Series A convertible preferred stock, with funds slated to support global commercialization of its CorPath GRX robotic surgical system. The Waltham, Mass.-based company will issue shares of Series A convertible preferred stock convertible into 20 million shares of common stock…
FDA Clears Software for Corindus CorPath GRX Surgical Robot
Corindus Vascular Robotics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for its CorPath GRX platform. Called “Rotate on Retract” (RoR), the proprietary software feature is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. It allows the operator…
Corindus Joins Mayo Clinic in Tele-Robotic Stenting Study
Corindus Vascular Robotics (OTC:CVRS) said today it is working with the Mayo Clinic to launch preclinical studies exploring the use of telestenting, a robotic treatment for percutaneous coronary interventions which can be operated by physicians in remote locations. The Waltham, Mass.-based surgical robotics company said that there is a global shortage of PCI-capable operators, and that telestenting…
Corindus touts 1st Corpath GRX system installation outside the US
Corindus Vascular Robotics (OTC:CVRS) today touted the first commercial installation of its CorPath GRx robotic surgical system outside of the US. The CorPath GRX platform, a robot-assisted system for percutaneous coronary interventions such as stenting, was purchased and installed at the Ahmedabad, India’s Apex Heart Institute, the Waltham, Mass.-based company said. Corindus said that it will…
Corindus Vascular Robotics to test-drive HeartFlow’s 3D cardiac imaging tech
Corindus Vascular Robotics (OTC:CVRS), a Massachusetts-based surgical robotics company, plans to utilize technology that creates 3D images of arteries for evaluating patients. Company officials said they’d employ California-based HeartFlow’s FFRct Analysis in a case series of robotic-assisted percutaneous coronary interventions to evaluate the technology’s role in clinical decision support. The testing will be done at hospitals…
CorPath GRX Robotic Center educates physicians on robotics in healthcare
Corindus Vasular Robotics opened its first international CorPath GRX Robotic Center in Tokyo to educate cardiologists on robotic-assisted percutaneous coronary interventions, the company announced today. “The opening of the first international robotic center represents an important milestone in the process of bringing precision vascular robotics to patients and physicians in Japan and around the world,”…
Corindus launches post-approval study for CorPath GRX coronary system
Corindus Vascular Robotics announced the first patient enrollment in a post-market study of its second-generation CorPath GRX System, a robot-assisted system for percutaneous coronary interventions such as stenting. “Enrollment of the first patient in the Precision GRX registry is a major milestone for the company and we look forward to the participation of leading centers…
Robotic surgery: Here’s everything you need to know
[<a href=”//storify.com/MedTechDaily/getting-started” target=”_blank”>View the story “Robotic surgery: Here’s everything you need to know” on Storify</a>]
Corindus touts high success rate in CorPath 200 PCI registry study
Corindus Vascular Robotics (NYSE:CVRS) released post-market findings from the Precision registry study of its CorPath 200 system used during percutaneous coronary interventions, touting high clinical and technical success rates. Data from the registry study was presented at the 2017 Society for Cardiovascular Angiography and Interventions Scientific Sessions last Friday, the Waltham, Mass.-based company said. The Precision…
Corindus registers for $60m mixed shelf offering
Corindus Vascular Robotics (NYSE:CVRS) this week registered for an upcoming mixed shelf offering worth up to $60 million. The company said that net proceeds from the round are currently slated to support further commercialization of its coronary robotic-assisted intervention programs as well as expanding the capabilities of its CorPath system, according to an SEC filing. The…
Corindus inks robotic R&D, training partnership deal with WakeMed
Corindus Vascular Robotics (NYSE:CVRS) said today it inked a partnership deal with WakeMed Health & Hospitals. Through the deal, the groups will develop a center which aims to advance clinical robotics research and train interventional cardiologists on robotic-assisted percutaneous coronary interventions using its CorPath GRX system, the Waltham, Mass.-based company said. “Our top priority is to provide…
Boston Scientific gets in on $45m private placement for Corindus Vascular Robotics
Boston Scientific (NYSE:BSX) got in on a $45 million private placement for Corindus Vascular Robotics (NYSE:CVRS) and the CorPath GRX device it’s developing for cardiac and peripheral vascular procedures. New investors BioStar Ventures, Consonance Capital and Hudson Executive Capital also participated, joining existing backers HealthCor Partners Management and Royal Philips (NYSE:PHG). “We are pleased to announce this financing and appreciate…